Effect of HSCT compared with chemotherapy only on outcome adjusted by known prognostic factors (Model I) and by risk stratification (Model II)
. | Disease-free survival . | Overall survival . | ||||
---|---|---|---|---|---|---|
Hazard ratio . | 95% CI . | P . | Hazard ratio . | 95% CI . | P . | |
Model I | ||||||
Chemo | 1 | — | — | 1 | — | — |
HSCT | .027 | .023 | ||||
6 mo | 0.96 | 0.50-1.82 | — | 0.74 | 0.28-1.95 | — |
1 y | 0.52 | 0.27-0.99 | — | 0.51 | 0.27-0.96 | — |
2 y | 0.28 | 0.10-0.80 | — | 0.35 | 0.15-0.84 | — |
3 y | 0.19 | 0.05-0.75 | — | 0.28 | 0.09-0.92 | — |
Age at diagnosis | ||||||
< 6 mo | 1.89 | 1.32-2.69 | .001 | 1.86 | 1.26-2.75 | .002 |
≥ 6-12 mo | 1 | — | — | 1 | — | — |
WBC counts | ||||||
< 100 g/L | 1 | — | — | 1 | — | — |
≥ 100-300 g/L | 1.38 | 0.91-2.09 | .127 | 1.50 | 0.94-2.38 | .088 |
≥ 300 g/L | 1.63 | 1.06-2.50 | .027 | 2.09 | 1.29-3.36 | .003 |
Immunophenotype | ||||||
B-cell, CD10− | 1 | — | — | 1 | — | — |
B-cell, CD10+ | 1.51 | 0.98-2.32 | .064 | 1.24 | 0.76-2.00 | .387 |
Other | 0.96 | 0.53-1.72 | .885 | 0.69 | 0.35-1.38 | .295 |
Prednisone response | ||||||
GPR | 1 | — | — | 1 | — | — |
PPR | 1.69 | 1.14-2.52 | .010 | 1.60 | 1.05-2.45 | .029 |
Model II | ||||||
Chemo | 1 | — | — | 1 | — | — |
HSCT | .032 | .014 | ||||
6 mo | 0.92 | 0.50-1.71 | — | 0.72 | 0.28-1.86 | — |
1 y | 0.53 | 0.28-0.98 | — | 0.51 | 0.28-0.93 | — |
2 y | 0.30 | 0.11-0.84 | — | 0.36 | 0.15-0.83 | — |
3 y | 0.22 | 0.06-0.81 | — | 0.29 | 0.09-0.92 | — |
Risk group | ||||||
Medium | 1 | — | — | 1 | — | — |
High | 2.56 | 1.85-3.53 | < .001 | 2.82 | 2.00-3.98 | < .001 |
. | Disease-free survival . | Overall survival . | ||||
---|---|---|---|---|---|---|
Hazard ratio . | 95% CI . | P . | Hazard ratio . | 95% CI . | P . | |
Model I | ||||||
Chemo | 1 | — | — | 1 | — | — |
HSCT | .027 | .023 | ||||
6 mo | 0.96 | 0.50-1.82 | — | 0.74 | 0.28-1.95 | — |
1 y | 0.52 | 0.27-0.99 | — | 0.51 | 0.27-0.96 | — |
2 y | 0.28 | 0.10-0.80 | — | 0.35 | 0.15-0.84 | — |
3 y | 0.19 | 0.05-0.75 | — | 0.28 | 0.09-0.92 | — |
Age at diagnosis | ||||||
< 6 mo | 1.89 | 1.32-2.69 | .001 | 1.86 | 1.26-2.75 | .002 |
≥ 6-12 mo | 1 | — | — | 1 | — | — |
WBC counts | ||||||
< 100 g/L | 1 | — | — | 1 | — | — |
≥ 100-300 g/L | 1.38 | 0.91-2.09 | .127 | 1.50 | 0.94-2.38 | .088 |
≥ 300 g/L | 1.63 | 1.06-2.50 | .027 | 2.09 | 1.29-3.36 | .003 |
Immunophenotype | ||||||
B-cell, CD10− | 1 | — | — | 1 | — | — |
B-cell, CD10+ | 1.51 | 0.98-2.32 | .064 | 1.24 | 0.76-2.00 | .387 |
Other | 0.96 | 0.53-1.72 | .885 | 0.69 | 0.35-1.38 | .295 |
Prednisone response | ||||||
GPR | 1 | — | — | 1 | — | — |
PPR | 1.69 | 1.14-2.52 | .010 | 1.60 | 1.05-2.45 | .029 |
Model II | ||||||
Chemo | 1 | — | — | 1 | — | — |
HSCT | .032 | .014 | ||||
6 mo | 0.92 | 0.50-1.71 | — | 0.72 | 0.28-1.86 | — |
1 y | 0.53 | 0.28-0.98 | — | 0.51 | 0.28-0.93 | — |
2 y | 0.30 | 0.11-0.84 | — | 0.36 | 0.15-0.83 | — |
3 y | 0.22 | 0.06-0.81 | — | 0.29 | 0.09-0.92 | — |
Risk group | ||||||
Medium | 1 | — | — | 1 | — | — |
High | 2.56 | 1.85-3.53 | < .001 | 2.82 | 2.00-3.98 | < .001 |
HSCT indicates hematopoietic stem cell transplantation; CI, confidence interval; WBC, white blood cell; GPR, good prednisone response; PPR, poor prednisone response; Chemo, chemotherapy only; and —, not applicable.